Elutia Inc.

Equities

ELUT

US05479K1060

Pharmaceuticals

Delayed Nasdaq 01:48:25 2024-04-29 pm EDT 5-day change 1st Jan Change
2.77 USD -0.36% Intraday chart for Elutia Inc. -5.14% +28.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Elutia Inc., Q4 2023 Earnings Call, Mar 07, 2024
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M MT
Transcript : Elutia Inc. - Special Call
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance CI
Elutia Inc. Amendments to Credit Agreement with SWK Funding LLC CI
Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating MT
Transcript : Elutia Inc., Q3 2023 Earnings Call, Nov 13, 2023
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (ELUT) ELUTIA Reports Q3 Revenue $6.1M, vs. Street Est of $7.3M MT
Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. for $34.6 million. CI
Top Premarket Gainers MT
Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC CI
Lake Street Initiates Elutia at Buy Rating With $3 Price Target MT
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed MT
Top Premarket Gainers MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms DJ
Elutia Inc. announced that it expects to receive $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC and other investor CI
Elutia Sells Orthobiologics Business Unit For Up to $35 Million MT
Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. for $35 million. CI
Aziyo Biologics Changes Name to Elutia MT
Aziyo Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Elutia Inc.
More charts
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.78 USD
Average target price
5.5 USD
Spread / Average Target
+97.84%
Consensus
  1. Stock Market
  2. Equities
  3. ELUT Stock
  4. News Elutia Inc.
  5. Elutia Sells Orthobiologics Business Unit For Up to $35 Million